Logo image of OVID

OVID THERAPEUTICS INC (OVID) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OVID - US6904691010 - Common Stock

1.615 USD
-0.03 (-2.12%)
Last: 12/30/2025, 12:09:54 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OVID. OVID was compared to 530 industry peers in the Biotechnology industry. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OVID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OVID has reported negative net income.
OVID had a negative operating cash flow in the past year.
OVID had negative earnings in 4 of the past 5 years.
In the past 5 years OVID reported 4 times negative operating cash flow.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

OVID has a Return On Assets (-56.90%) which is comparable to the rest of the industry.
OVID has a Return On Equity (-81.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROIC N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OVID has more shares outstanding
The number of shares outstanding for OVID has been increased compared to 5 years ago.
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

OVID has an Altman-Z score of -5.18. This is a bad value and indicates that OVID is not financially healthy and even has some risk of bankruptcy.
OVID has a worse Altman-Z score (-5.18) than 62.45% of its industry peers.
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.18
ROIC/WACCN/A
WACC8.78%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

OVID has a Current Ratio of 4.24. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
OVID has a Current ratio of 4.24. This is comparable to the rest of the industry: OVID outperforms 50.75% of its industry peers.
A Quick Ratio of 4.24 indicates that OVID has no problem at all paying its short term obligations.
With a Quick ratio value of 4.24, OVID perfoms like the industry average, outperforming 51.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for OVID have decreased by -6.38% in the last year.
The Revenue has grown by 946.55% in the past year. This is a very strong growth!
Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%

3.2 Future

Based on estimates for the next years, OVID will show a decrease in Earnings Per Share. The EPS will decrease by -3.38% on average per year.
The Revenue is expected to grow by 68.32% on average over the next years. This is a very strong growth
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y68.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

OVID's earnings are expected to decrease with -12.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%

More info and screens

0

5. Dividend

5.1 Amount

OVID does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

OVID THERAPEUTICS INC

NASDAQ:OVID (12/30/2025, 12:09:54 PM)

1.615

-0.03 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners40.54%
Inst Owner Change2.23%
Ins Owners5.51%
Ins Owner Change0.56%
Market Cap115.00M
Revenue(TTM)6.61M
Net Income(TTM)-36.33M
Analysts88
Price Target4.26 (163.78%)
Short Float %6.99%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.21%
Min EPS beat(2)-11.2%
Max EPS beat(2)63.62%
EPS beat(4)2
Avg EPS beat(4)18.8%
Min EPS beat(4)-11.2%
Max EPS beat(4)63.62%
EPS beat(8)5
Avg EPS beat(8)-9.79%
EPS beat(12)8
Avg EPS beat(12)-3.55%
EPS beat(16)11
Avg EPS beat(16)1.7%
Revenue beat(2)1
Avg Revenue beat(2)3959.29%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)7920.11%
Revenue beat(4)2
Avg Revenue beat(4)2003.21%
Min Revenue beat(4)-60.64%
Max Revenue beat(4)7920.11%
Revenue beat(8)6
Avg Revenue beat(8)1066.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.6%
PT rev (3m)22.79%
EPS NQ rev (1m)0.95%
EPS NQ rev (3m)13.59%
EPS NY rev (1m)-6.41%
EPS NY rev (3m)3.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-55.57%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.4
P/FCF N/A
P/OCF N/A
P/B 2.57
P/tB 2.57
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.09
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -5.18
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)104.96%
Cap/Depr(5y)109.64%
Cap/Sales(3y)52.29%
Cap/Sales(5y)32.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y68.32%
EBIT growth 1Y41.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.78%
OCF growth 3YN/A
OCF growth 5YN/A

OVID THERAPEUTICS INC / OVID FAQ

Can you provide the ChartMill fundamental rating for OVID THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to OVID.


What is the valuation status for OVID stock?

ChartMill assigns a valuation rating of 0 / 10 to OVID THERAPEUTICS INC (OVID). This can be considered as Overvalued.


How profitable is OVID THERAPEUTICS INC (OVID) stock?

OVID THERAPEUTICS INC (OVID) has a profitability rating of 1 / 10.


What is the earnings growth outlook for OVID THERAPEUTICS INC?

The Earnings per Share (EPS) of OVID THERAPEUTICS INC (OVID) is expected to decline by -30.82% in the next year.